Depostat

designed to reduce the risk of metastatic spread in endometrial carcinoma

Pre-operatively Depostat
exerts a strong anti-mitotic effect on endometrial tissue.
reduces the friability of the tumour.
may prevent tumour emboli from becoming established metastases.

Post-operatively Depostat
inhibits through its strong anti-mitotic properties any metastatic spread which has already occurred.
can be used synergistically with cytotoxic agents.
may improve the quality of life of those patients with inoperable conditions.

Depostat
does not impair adrenal function, and side-effects are rare.

Depostat
another step forward in the treatment of cancer

Dosage and administration
Endometrial carcinoma, before hysterectomy and for advanced disease. A well-tolerated adjunct to other therapy. To inhibit metastatic spread, before and after operation. 200-400 mg intramuscularly every five days, starting immediately following diagnosis and continuing for a minimum of 12 weeks.

For treating existing metastases: 200-400 mg intramuscularly every five days. If the metastases are hormone-responsive, improvement will be observed after 6-12 weeks of therapy. Treatment should then be continued as long as it appears beneficial.

The standard dosage of Depostat is 200 mg weekly by intramuscular injection, but in view of its excellent tolerance, this dosage can confidently be increased. In trials, 300 mg and 400 mg weekly have been used.

Contra-indications, warnings, etc
Rarely, local reactions may occur at the site of injection. Depostat should not be given during pregnancy. Exacerbation of bronchial asthma, epilepsy and migraine may sometimes occur.

Tolerances: Tolerance of Depostat is excellent. In patients with chronic liver damage it is advisable to check liver function at intervals during long-term treatment or repeated courses of Depostat. Transient moderate rises in bromosulphalein retention and serum transaminases have occasionally been observed but have always proved harmless.

Pharmaceutical precautions Storage. Store in cool, dry conditions away from strong sunlight. Shelf-life five years.

Legal category S4B.

Package quantities 5 ampoules of 2 ml.

Further Information Nil.

Product licence number 0053/0018.

© SCL November 1973 U.K. 10805

Schering
Schering Chemicals Limited,
Pharmaceutical Division,
Burgess Hill, Sussex, RH15 9NE.